Definium Therapeutics Set to Unveil Phase 3 MDD Trial Results
Event summary
- Definium Therapeutics will disclose topline results from its Phase 3 Emerge study in major depressive disorder (MDD) on June 22, 2026.
- The study evaluated a single 100 µg dose of DT120 ODT versus placebo in 149 participants across 20 sites.
- Primary endpoint is change from baseline in MADRS total score at Week 6.
- Emerge is one of two pivotal Phase 3 studies; Ascend includes a low-dose arm and confounded randomization design.
The big picture
Definium Therapeutics is advancing a novel approach to psychiatric disorders by leveraging psychedelic-inspired therapeutics. The Phase 3 results will be critical in determining the viability of DT120 ODT as a potential breakthrough treatment for MDD, an area with significant unmet medical need. Success could position Definium as a leader in the emerging field of psychedelic medicine.
What we're watching
- Clinical Efficacy
- Whether DT120 ODT demonstrates statistically significant improvement over placebo in MDD patients.
- Regulatory Pathway
- How the confounded randomization design in Ascend may influence FDA review and approval timelines.
- Market Positioning
- The pace at which Definium can scale commercialization if DT120 ODT proves effective.